GlassScriptPhysician profile
Kendral Knight
NPI 1275783250
$2,111.42
in general payments reported to CMS, 2019-2025
25 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2021: $101 · 2022: $135 · 2023: $265 · 2024: $541 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264 · Education: $22.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.09 |
| Education | $22.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $439.75 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $298.67 | 2022-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $186.29 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $137.00 | 2019-2021 | |
| Opko Pharmaceuticals, LLC | $133.55 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $123.51 | 2019 | |
| Outset Medical INC | $117.26 | 2023 | |
| Baxter Healthcare | $86.34 | 2019 | |
| Amgen INC. | $80.60 | 2024 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $69.64 | 2022-2025 | Tarpeyo |
| Nxstage Medical, INC. | $69.45 | 2019 | |
| Glaxosmithkline, LLC. | $44.38 | 2021-2024 | Benlysta |
| Ardelyx, INC. | $40.32 | 2024-2025 | Ibsrela |
| Horizon Therapeutics Plc | $36.87 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.52 | 2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $33.63 | 2025 | Terlivaz |
| Lilly USA, LLC | $27.75 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $24.72 | 2025 | |
| Daiichi Sankyo INC. | $23.76 | 2021 | |
| Pharmacosmos Therapeutics INC. | $23.12 | 2025 | Monoferric |
| Novo Nordisk INC | $21.16 | 2024 | Rivfloza |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.41 | 2022 | |
| Fresenius USA Marketing, INC. | $12.98 | 2021 | |
| Vifor Pharma, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendral Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.